The FDA has declined to approve King Pharmaceuticals' experimental imaging agent CorVue, saying it needs to see more information before it can make a final decision. King (KG) had hoped to win an approval for the imaging agent, which has been tested in assessing the risk of coronary artery disease. Analysts were left guessing just how big a setback this is for King, which didn't specify exactly what the FDA is looking for. Report